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Abstract
Background: Apoptosis is thought to play a role in the pathogenesis of severe dengue and the release of cell-free DNA into
the circulatory system in several medical conditions. Therefore, we investigated circulating DNA as a potential biomarker for
severe dengue.
Methods and Findings: A direct fluorometric degradation assay using PicoGreen was performed to quantify cell-free DNA
from patient plasma. Circulating DNA levels were significantly higher in patients with dengue virus infection than with other
febrile illnesses and healthy controls. Remarkably, the increase of DNA levels correlated with the severity of dengue.
Additionally, multivariate logistic regression analysis showed that circulating DNA levels independently correlated with
dengue shock syndrome.
Conclusions: Circulating DNA levels were increased in dengue patients and correlated with dengue severity. Additional
studies are required to show the benefits of this biomarker in early dengue diagnosis and for the prognosis of shock
complication.
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Introduction
Dengue virus (DV), an arthropod-borne human viral pathogen
with four distinct serotypes (DV-1, DV-2, DV-3, and DV-4),
belongs to the genus Flavivirus of the family Flaviviridae. In the last
two to three decades, dengue has become a major public-health
burden in tropical and subtropical areas of the world, mostly in
Southeast Asia and Western Pacific Regions. Dengue disease
ranges from asymptomatic or self-limiting dengue fever to severe
dengue characterized by plasma leakage (dengue hemorrhagic
fever, DHF) that can lead to a life-threatening syndrome (dengue
shock syndrome, DSS). Besides, severe dengue was also defined by
severe bleeding, and/or severe organ impairment [1]. About 50–
100 million dengue infections are estimated to occur annually,
including about 250,000–500,000 cases of DHF/DSS [2]. So far,
there is no effective vaccine or antiviral drug against the disease.
Although mortality can reach 10–20% of severe cases [2], early
appropriate treatment can reduce it to less than 1% [1]. Hence,
the World Health Organization (WHO) encourages research on
the development of new methodologies to serve as dengue severity
markers [3]. In relation to this, a series of biological markers such
as DV-nonstructural protein 1 (NS1), immune cytokines, and
markers of endothelial cell damage and dysfunction have been
investigated [4]. Remarkably, neopterin, which is synthesized by
macrophages as an indicator of pro-inflammatory immune status,
was reported to be a potential marker for severe dengue infection
[5]. Furthermore, increased titers of soluble thrombomodulin [6],
hyaluronan [7], or decreased levels of inter-a inhibitor proteins in
dengue infection are also correlated with disease severity [8].
However, no effective marker for severe dengue prediction has
been found so far [4].
The pathogenesis of DHF/DSS is still not completely
understood. Various mechanisms have been suggested, including
antibody-dependent enhancement in secondary dengue infection
[9], memory T cell-mediated pathogenesis [10], suppressed Th1/
predominant Th2 responses [11], cytokine tsunami [12], and anti-
NS1 antibodies that cross-react with vascular endothelium [13].
Additionally, the virulence of the virus strain [9,14] and host
genetics [15] may influence the outcome of a dengue infection.
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plasma of patients with ovarian cancer [16], rheumatoid arthritis
[17], and sepsis [18]. Apoptotic cells are suggested to be the main
source for release of this cell-free DNA [19], which can activate
innate immunity [20,21]. In dengue infection, apoptosis could play
a role in the pathogenesis of dengue severity. Apoptotic cell death
following dengue infection is proposed to cause liver failure [22],
damage to the central nervous system in a mouse model [23], and
induce vascular permeability [24]. Furthermore, dengue infection
has been shown to cause an increase in peripheral blood
mononuclear apoptosis, which is also correlated with dengue
severity [25]. However, to our knowledge, the increase of
circulating human DNA in viral infectious diseases has not yet
been investigated. Hence, we investigated the level of cell-free
circulating DNA in acute DV infections, and its association with
disease severity.
Materials and Methods
Study design
A hospital-based case control study was performed on children
aged 6 months to 15 years with suspected dengue infections from
2006 to 2007 in the Children’s Hospital No. 2 in Ho Chi Minh
City and the Center for Preventive Medicine in Vinh Long
province, Vietnam. This study was approved by the institutional
ethical review committees of the Institute of Tropical Medicine,
Nagasaki University, and the Pasteur Institute in Ho Chi Minh
City. Informed consent was required for all subjects from the
parents or guardians upon enrolment.
Selection criteria
All of the dengue cases satisfied the 1997 WHO diagnostic
criteria [26]: DF, an acute febrile with at least two of the symptoms
such as headache, retro-orbital pain, myalgia, arthralgia, rash,
hemorrhagic manifestations, or leukopenia; DHF with fever or
history of acute fever lasting 2–7 days, bleeding signs, thrombo-
cytopenia (100,000 cells per mm
3 or less), or evidence of plasma
leakage (hemoconcentration, pleural effusion, and ascites); DSS,
symptoms of DHF plus shock signs including weak and rapid
pulse, narrowing of the pulse pressure (,20 mm Hg), or
hypotension with cold, clammy skin and restlessness. The extent
of hemoconcentration was evaluated by comparing the maximum
hematocrit to the minimum value recorded during hospitalization.
A positive confirmed laboratory test was made when the result of
dengue virus isolation was positive or RT-PCR assay determined a
dengue serotype, or when there was a positive anti-DV IgM
antibody-capture ELISA, a positive seroconversion, or a $4-fold
increase in anti-DV IgG titres between acute and convalescent
samples. The cases were diagnosed as secondary infection if the
DV IgM/IgG ratio was ,1.8 [27].
All patients hospitalized in the first 96 h of illness and
corresponding to the above criteria were enrolled in the study.
Patients who were suspected as dengue fever but had negative
serological and virological diagnostic tests with dengue infection
were defined as having other non-dengue febrile illnesses (OFIs).
School children living in Ho Chi Minh City who had no symptoms
of DV infection or other diseases, and tested negative in anti-DV
IgM and IgG antibody-capture ELISA, were chosen as a healthy
control group.
Sample collection
Blood samples were drawn into EDTA tubes at the time of
enrolment and in the convalescent phase prior to discharge from
the hospital. Plasma was separated by centrifugation at 3000 rpm
for 10 min and divided into two tubes: one used for dengue
confirmation while the other was stored at 280uC and centrifuged
again at 3000 rpm for 10 min before being used for cell-free DNA
quantification.
Dengue diagnosis
Dengue virus isolation using the C6/36 cell line as described
previously [28,29] and viral identification by a direct and indirect
fluorescent antibody technique with monoclonal antibodies
supplied by the Centers for Disease Control and Prevention (For
Collins, CO, USA) [30], and molecular detection of the dengue
virus genome by a Ready-To-Go reverse transcriptase PCR test kit
(Amersham, MA, USA) [31], were carried out immediately on the
acute plasma sample. Serological assays for anti-DV IgM and IgG
by IgM-and IgG-capture ELISA (in-house Kit of the Pasteur
Institute, HCMC) were carried out on both the acute and
convalescent plasma samples, collected at $3-day intervals [27].
Measurement of circulating DNA by Picogreen
fluorometric degradation assay
The Quant-iT PicoGreen dsDNA Reagent and Kit was
purchased from Invitrogen (Life Technologies Japan). Lambda
DNA of known concentration was serially diluted and added to
pooled plasma of 10 healthy donors with negligible DNA
concentration to make standard DNA samples. Three microliters
of standard DNA samples were diluted in 100 ml of TE buffer
(10 mM Tris-HCl, 1 mM EDTA, pH 7.5) and incubated at 37uC
for 1 h in the presence or absence of 6 mg bovine pancreatic
DNase I (Sigma) activated in 10 mM MgCl2. In the preliminary
test, more than 90% of added DNA was degraded in this
experimental condition (data not shown). Then, an equal volume
of the PicoGreen dye diluted 1:200 in TE buffer was added to the
reaction to make a final volume of 200 ml per well in a black 96-
well microplate (Corning Japan, Tokyo, Japan). After incubation
in the dark for 15 min, the fluorescent signal of the sample was
measured at 485 nm excitation and 535 nm emission using Perkin
Elmer ARVO
TM MX-1420. Each sample was performed in
duplicate. The reduction in fluorescent intensity between non-
treated and DNase-treated samples was calculated, and then
plotted against the standard DNA concentration to make a
standard curve. Linearity was found within a DNA concentration
range of 0–26667 ng/ml (Figure S1). The intra-assay coefficient of
variation (CV) was 2.1–15.5%, while the inter-assay coefficient of
variation was 0.8–23.8% (Table S1). The limits of quantification
(LOQ) and detection (LOD) were 179 and 68 ng/ml, respectively.
LOQ was determined as the mean concentration plus 10 standard
deviations (SD) of a blank sample without DNA, and LOD was
calculated by adding three SDs to the mean concentration of the
blank. Hence, this linear line was used as a standard curve to
estimate DNA amount (L’) in 3 ml of plasma, and then the DNA
level was expressed in nanograms per milliliter based on the
following equation:
L~L0|V{1|1000
where L is concentration of DNA in plasma (ng/ml), and V is
volume of plasma added to the reaction (3 mL).
The degradation fluorometric PicoGreen method was further
validated by quantitative real-time PCR, which is considered to be
the standard method for cell-free DNA quantification [16,32]. A
total of 84 random plasma samples from 20 healthy children and
64 dengue patients (22 DF, 30 DHF, 12 DSS) were selected for
DNA extraction, and the amplification reaction followed a
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GAPDH gene was used to represent the DNA level in the plasma
[16,32] (at least 400 ml of plasma was used; details of the method
are described in the Methods S1). The correlation between the two
methods was analyzed by a Spearman rank test. Our results
demonstrated that the fluorometric degradation method was
highly correlated with real-time PCR (r=0.78, P,0.0001) (Figure
S2). This correlation coefficiency was higher than that of
nucleosome-specific ELISA and real-time PCR, as previously
reported [33]. Moreover, the PicoGreen method consumed very
small volumes of plasma for each reaction, and had advantages of
lower time, cost, and labor compared to the real-time PCR
method. Hence, the degradation fluorometric PicoGreen assay
was applied for all samples in this study.
Statistical analysis
All statistical analyses were performed using STATA software,
version 8.0. The Skewness and Kurtosis test was used for testing
the normal distribution of continuous variables. Student’s t test
was used for continuous variables normally distributed, while
Mann-Whitney tests were used for continuous variables which
were not normally distributed. Correlation between the two
methods was analyzed by a Spearman rank test. x
2 analysis was
used for categorical variables. Fisher’s exact test was used when the
number was less than 5. The difference was considered significant
at P,0.05. A multivariate logistic regression model was used to
find the independent predictive value of the biomarker on disease
outcome.
Results
Study population characteristics
A total of 281 subjects, including 194 dengue patients, 44 OFIs,
and 43 healthy children were enrolled in this study, and their
characteristics are summarized in Table 1. Among the 194
patients, 61 were DF, 76 were DHF, and 57 were DSS according
to the 1997 WHO classification. There were no differences in sex
and age between the control and dengue groups. The mean ages
were lower in the DSS group compared to the DHF group
(P,0.01) and lower in the OFI group compared to the DF group
(P,0.01). For the laboratory parameters, the leukocyte number
was found to be lower in the DF than the OFI group (P,0.001).
Additionally, a higher hematocrit (P,0.001) and a lower platelet
count (P,0.01) were found in the DSS group compared to the
DHF or DF groups and in the DF group compared to the OFI
group. Overall, 119 (61.3%) of 194 children with dengue had
secondary infection. The rate of secondary infection was 40
(85.1%) of 47 cases in DSS, significantly higher than the 45
Table 1. Clinical characteristics, laboratory parameters, and plasma DNA levels.
Characteristics
Controls
n=43
OFI
n=44
DF
n=61
DHF
n=76
DSS
n=57 P{
Age (years) 8.563.9 6.164.5 9.5639 . 9 63.3 8.363.3 ,0.01
a,d
Female 22 18 30 37 34 0.2
Sampling day na
3
rd day of illness 19 17 18 7 0.036
b
4
th day of illness 25 44 58 50 -
DV serotypes na na
DV-1 21 27 13 0.5
DV-2 14 23 19 0.02
b
DV-3 10 7 3 0.1
DV-4 3 0 0 0.09
DV-1,-4 0 1 1 -
Unknown 13 18 21 -
Secondary/Primary na na
Primary 17 21 7 -
Secondary 34 45 40 ,0.05
a,b
Unknown 10 10 10 -
HCT (%)* na 38 (31–45) 41.1 (33.1–47.3) 41.2 (30–50.8) 45.1 (33.7–59.5) ,0.001
a,b,d
PLT (610
3/ml)* na 150 (93–315) 114 (63–223) 94 (25.1–232) 62 (15.1–166) ,0.01
a,b,c,d
WBC (610
3/ml)* na 4.4 (2.3–12) 3.3 (1.4–7.63) 3.3 (0.95–16.1) 3.6 (1.52–15.2) ,0.001
d
DNA (ng/ml)* 143.8 (0–494.2) 158.4 (0–590.6) 322.8 (0–5890.5) 663.3 (0–14798.2) 2119.1 (49–42240.2) ,0.02
a,b,c,d,e
DF, dengue fever; DHF, dengue hemorrhagic fever; DSS, dengue shock syndrome; SD, standard deviation; na, not applicable; HCT, hematocrit, PLT, platelet, WBC, white
blood cell; DV, dengue virus.
*on time of enrolment. Nineteen OFI persons’ WBC were not recorded.
{Mean 6 SD, Student’s t test for continuous variables normally distributed; median (minimum, maximum), Mann-Whitney test for continuous variables not normally
distributed; x
2 analysis used for categorical variables; Fisher’s exact test for small expected number;
abetween DHF and DSS patients;
bbetween DF and DSS patients,
cbetween DF and DHF patients,
dbetween DF and OFI patients,
ebetween control and DF.
doi:10.1371/journal.pone.0025969.t001
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(P,0.05). In 142 confirmed DV serotypes, DV-1 and DV-2
accounted for the majority of the dengue population (43% and
39.4%, respectively), followed by DV-3 (14.1%) and DV-4 (2.1%).
The prevalence of DV-2 was 19 (54.3%) of 35 cases in DSS and 14
(29.2%) of 48 cases in DF patients with statistical significance
(P=0.02).
Circulating DNA levels measured by the PicoGreen
fluorometric degradation assay
The median circulating DNA levels in the five study groups are
shown in Table 1, and the distribution of the DNA values for each
group according to the blood test day is shown in Figure 1. Our
results showed that the median DNA levels in all dengue groups
were significantly higher than those of the control and OFI groups
(P,0.001). Moreover, elevated DNA levels corresponded to the
severity of dengue disease: 2119.1 ng/ml in DSS, 663.3 ng/ml in
DHF, and 322.8 ng/ml in DF, which were significantly different.
Remarkably, circulating DNA levels were significantly higher in
DSS than in DHF or DF and higher in DF than OFI, regardless of
whether the blood test day was done on day 3 or 4 from the onset
(Figure 1). Among the DSS population, 9 (15.8%) of 57 patients
were admitted to the hospital in early stage (1–2 days before shock)
whereas others entered to shock situation at the admission day.
However, the DNA level was elevated early, even in 1–2 days
before appearance of shock in 9 DSS cases and significantly higher
in this DSS group than non-shock group (P=0.005) (Figure S3).
Additionally, 84 random samples were used for DNA extraction,
followed by multiplex real-time PCR (detailed in supporting
information) for nuclear DNA (nDNA) and mitochondrial DNA
(mtDNA) quantification. Similarly, the median levels of nDNA
and mtDNA in dengue groups were significantly higher than in
the control. Increased nDNA levels were also found to be highest
in DSS cases, while the mtDNA levels were not significantly
different among the dengue groups (Figure S4).
Correlation of circulating DNA levels with dengue
severity, demographic, clinical, and laboratory features
Since several risk factors are reportedly associated with dengue
severity,wefurtheranalyzedthecorrelationofcirculatingDNAlevels
with severity and these risk factors. As shown in Table 2, elevated
levels of DNA positively correlated with the severity of dengue
(P,0.0001), secondary infection (P=0.0003), virulent strains of
dengue virus (P=0.04), and hematocrit (P,0.0001), but inversely
correlated with platelet count (P,0.0001) and male gender (P=0.04).
In contrast, no significant correlation was observed between DNA
levels and age or white blood cell (WBC) count (P.0.05).
Multivariate logistic regression analysis for DSS
predictors
Since several variables also correlated with dengue severity, we
investigated whether circulating DNA levels could independently
predict DSS from non-DSS cases (DHF/DF). The results in
Table 3 show that DNA levels independently correlated with DSS
in the presence of age, gender, hematocrit, WBC, and platelet
counts in a multivariate model (P=0.02).
Discussion
In our study, cell-free circulating DNA levels were shown to be
increased among dengue patients compared with control and OFI
groups. This increase was highest in the DSS group, regardless of
whether it was the third or fourth day of illness and even in 1–2 days
before shock occurred in some DSS cases. Additionally, there was a
positive correlation between DNA levels and dengue severity, as well
as pathological features such as hematocrit, secondary infection, and
Figure 1. Circulating DNA levels among study groups according to the day of the blood test. Day 3 and 4 indicate the duration after the
onset of high grade fever. Box-plots graphs extend from the 25
th to the 75
th percentile, and the line at the middle is the median. The error bars
extend down to the lowest value and up to the highest. (The outliers are not shown). The Mann-Whitney test was used for comparisons of DNA levels
between groups.
doi:10.1371/journal.pone.0025969.g001
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multivariable analysis showed an independent correlation between
shock syndrome and the circulating DNA level. This result suggests
that the circulatingDNA level couldbeevaluated for prognostic value
in further studies. Similarly, the prognostic value of circulating DNA
h a sb e e ns h o w ni np a t i e n t sw i t ht r a u m a[ 3 4 ]a n da c u t es t r o k e[ 3 5 ]
with high sensitivity and specificity. However, the limitation of the
present study is that we did not monitor the dynamic kinetics of cell-
free DNA in acute phase of dengue infection and the majority of
blood samples for measurement of DNA level in DSS patients were
collected around the time that shock occurred. One of the common
difficulties in investigating predictor for dengue severity is that the
sampling time should be performed early whereas the majority of
dengue patients present to hospital clinicians late during their illness,
perhaps on day 3 or 4 of fever [1]. Hence, further prospective studies
should be performed at primary care center for validating the benefit
of circulating DNA tests in early prognosis of dengue shock
syndrome.
Among various techniques established in the investigation of
cell-free DNA in plasma/serum, real-time PCR is currently
considered as the standard method [16,32], although it is limited
by DNA loss via binding columns during extraction. Recently, a
direct fluorimetric DNA quantitative assay using the SYBR Gold
dye without a purification step has been developed [36]. This assay
is simple and fast, but may be affected by differential levels of
proteins and particular substances. In contrast, our degradation
fluorometric PicoGreen method generates a DNA-specific fluo-
rescent signal within 90 min and uses only two small aliquots of a
particular sample. Furthermore, there was a good correlation
between the PicoGreen method and the standard real-time PCR
(Figure S2), suggesting that PicoGreen coupled with DNase can be
employed as a simple and efficient clinical method for measuring
circulating DNA levels. The level of plasma DNA varies within a
broad range, but the median is no more than 60 ng/ml in healthy
donors according to different methods using samples after DNA
purification [37]. In our direct method without extraction, the
normal level of plasma DNA estimated in our study (range: 0–
494.2 ng/ml) was fairly similar to that obtained using a SYBR
Gold direct fluorometric assay (4716203 ng/ml). To investigate
the type of DNA released into circulation during the acute phase
of dengue infection, we also quantified nDNA and mtDNA in 84
samples. Both nDNA and mtDNA levels were elevated in dengue
infection. The level of nDNA was associated with dengue severity,
agreeing well with the circulating DNA levels measured by the
PicoGreen method. In contrast, no significant difference was
found between dengue groups regarding of mtDNA levels. This is
probably due to the fact that the smaller mtDNA molecule (16,597
base-pairs) could be more quickly removed from circulation due to
the increased vascular permeability in severe dengue cases (DHF/
DSS), via the delivery systems of body, or excretion into urine
compared with the larger nDNA genome (3 billion base-pairs). In
addition, based on our results shown in Figure S3, the majority of
circulating DNA originated from nDNA but not mtDNA.
A limiting factor of many studies of circulating DNA is that the
half-life of cell-free DNA in circulation is short (4–30 min) [38,39]
due to the effects of serum nucleases, rapid removal from
circulation by the liver and kidneys, and redistribution through
organs and tissues [37]. Although the mechanism by which cell-
free DNA is elevated in dengue patients is unknown, it is probably
released from apoptotic cells, which have been found in the liver,
brain, intestinal, and lung tissues during dengue infection [40].
Similarly, a study on Thailand patients found a higher rate of
apoptotic PBMCs in DHF than in DF cases [41]. This DV-
induced apoptotic process is triggered by both extrinsic and
intrinsic pathways [42], and is thought to be involved in regulation
of innate and adaptive immune responses to DV infection [25].
Moreover, failure of plasma DNA removal by the liver and
kidneys due to multiple organ dysfunctions in severe dengue
infections may contribute to the elevation of circulating DNA.
In our study, certain pathological features (secondary infection,
hemoconcentration, and platelet count) were associated with dengue
shock. These findings support a study from Pham et al., which
proposed that hematocrit of more than 50%, a platelet count of less
than 75,000/mm
3, and hepatomegaly were predictive features of
DSS [43]. Tantracheewathorn et al. also found that a hemoconcen-
tration of morethan 22% and secondary infection are risk factors for
DSS [44]. Another factor associated with DSS in this study is the
DV-2 serotype, which is proposed to have higher virulence in
comparison to other serotypes [45]. Similar results were obtained by
Nguyen et al., who showed that DV-2 is significantly more prevalent
in DSS than DHF (70% and 45.5%, respectively) [15]. On the other
hand, strong leukopenia, one of the typical manifestations of dengue
disease that differentiates it from other febrile illnesses [46], was also
noted among dengue patients in this study.
Table 2. Correlation of DNA level with the severity of dengue disease and other pathological features.
Characteristics Age F/M Severity HCT PLT WBC P/S Serotype*
Correlation coefficient 20.011 20.12 0.63 0.35 20.57 0.13 0.28 0.17
P value 0.85 0.04 ,0.0001 ,0.0001 ,0.0001 0.065 0.0003 0.04
N 281 281 237 208 208 208 164 140
F/M: female/male. P/S: primary/secondary.
*serotype with increasingly virulent strain (DV-4/3/1/2). Correlation findings by Spearman rank test. Significant P values are underlined.
doi:10.1371/journal.pone.0025969.t002
Table 3. Multivariate logistic regression model to predict DSS
versus non-shock cases (DHF/DF).
Predictor OR (95%CI) P value
Adjusted OR
(95%CI) P value
Age 0.88 (0.8–0.97) 0.009 0.82 (0.7–0.94) 0.005
Gender 0.65 (0.35–1.21) 0.2 0.93 (0.4–2.1) 0.8
DNA (ng/ml)* 1.03 (1.02–1.05) 0.0 1.02 (1.003–1.04) 0.02
WBC (610
3/ml)* 1.08 (0.94–1.23) 0.3 0.83 (0.66–1.05) 0.1
HCT (%)* 1.21 (1.12–1.31) 0.0 1.19 (1.07–1.32) 0.001
PLT (610
3/ml)* 0.96 (0.94–0.97) 0.0 0.97 (0.95–0.98) 0.0
*Odds ratio represents the incremental odds of DSS for every unit increase of
100 nanogram per milliliter in DNA level, or 1000 cells per microliter in WBC, or
1 percent in HCT, or 1000 platelet per microliter in PLT.
doi:10.1371/journal.pone.0025969.t003
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free DNA levels in plasma of dengue patients. Circulating DNA
levels were independently associated with dengue severity.
However, further large prospective studies are required to confirm
the accuracy of circulating DNA levels in early prognosis of DSS.
Supporting Information
Figure S1 Standard curve of the fluorometric degrada-
tion method using three microliters of normal plasma
with calf Lambda DNA. The equation of the straight line is
y=2.381x, and the R
2 is 0.999.
(TIF)
Figure S2 Correlation between real-time PCR and the
PicoGreen fluorometric degradation method. The Spear-
man correlation showed an r value of 0.78, P,0.0001, n=84.
(TIF)
Figure S3 Levels of circulating DNA in DSS patients
admitted to hospital in early stage (before shock) and in
critical stage (aroundtimeofshock). Box-plots graphs extend
from the 25
th to the 75
th percentile and the line at the middle is the
median. The error bars extend down to the lowest value and up to
the highest. (The outliers are not shown). The Mann-Whitney test
was used for comparisons of DNA levels between groups.
(TIF)
Figure S4 Levels of nuclear DNA (A) and mitochondrial DNA
(B) in healthy children and patients with varying dengue severity
determined by real-time PCR. Box-plots graphs extend from the
25
th to the 75
th percentile and the line at the middle is the median.
The error bars extend down to the lowest value and up to the
highest. (The outliers are not shown). The Mann-Whitney test was
used for comparisons of DNA levels between group.
(TIF)
Table S1 Precision and recovery of the fluorometric
degradation method.
(DOC)
Methods S1 Detection of nuclear DNA (nDNA) and
mitochondrial DNA (mtDNA) by real-time quantitative
PCR.
(DOC)
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